Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
A Multicenter, Open-label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005%, in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis
Sponsor: GlaxoSmithKline
This PHASE1 trial investigates Psoriasis and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Phase: PHASE3 → PHASE1
-
Feb 2017 — Jun 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- Mayne Pharma International Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .